Study on Thrombosis Therapy in German Cancer Patients

The study aims to document the flow of German patients with cancer and acute deep vein thrombosis from first visit to diagnosis and treatment, the applied diagnostic procedures, and therapy modalities.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Cardiovascular Diseases Deep Vein Thrombosis Embolism Embolism and Thrombosis Lung Diseases Neoplasms Pulmonary Embolism Respiratory Tract Diseases Thrombosis Vascular Diseases Venous Thrombosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Prof. Dr. Axel Matzdorff

Saarbrücken, Saarland, 66111, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patient with cancer and acute deep vein thrombosis and/or pulmonary embolism

Exclusion criteria

life expectancy less that 6 months
age less that 18 years

Treatment and study plan

no intervention is being made

Other

This is a Non-Interventional Study (NIS)

Primary outcomes

treatment time on low molecular weight heparin

Time frame: 1 year

Secondary outcomes

patient pathways

Time frame: 1 year

data collection on patient pathway: who is the referring physician, physician who diagnoses deep vein thrombosis (DVT)
risk factors for DVT

Time frame: 1 year

Sponsors and collaborators

Lead sponsor

LEO Pharma

Industry

Registry information

Important dates

Study start: 2012
Primary completion: 2013
Study completion: 2013
First posted: Mar 21, 2012
Registry last updated: Aug 15, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed